Quality checklist |
Selection |
1. Assignment for treatment – any criteria reported? (If yes, 1-star)
|
2. How representative was the ‘reference’ group (MI) in comparison to
the ‘alternative’ group (MS); (If yes, 1 star, no star if the patients
were selected or selection of group was not described)
|
Comparability |
Comparability variables: (1) age; (2) gender; (3) renal function; (4)
extracardiac arteriopathy; (5) poor mobility; (6) previous cardiac
surgery; (7) chronic lung disease; (8) active endocarditis; (9) urgency;
(10) DM; (11) NYHA; (12) CCS IV; (13) LV function; (14) recent coronary
syndrome; (15) pulmonary hypertension; (16) urgency; (17) BSA; (18)
tumor type (histology / location); (19) tumor size.
|
3. Groups comparable for 1, 2, 3, 4, 5, 6, 7, 8, 9 (If yes, 1-star was
assigned for each of these. No star was assigned if the groups differed)
|
4. Groups comparable for 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 (If yes,
1-star was
assigned for each of these. No star was assigned if the two groups
differed).
|
Outcome assessment |
6. Clearly defined outcome of interest (If yes, 1-star).
|
7. Follow-up (1-star if described).
|
BSA=Body surface area. CCS= Canadian Cardiovascular Society.
IDDM=insulin dependent diabetes mellitus; MI= minimally invasive.
MS=median sternotomy. NYHA=New York Heart Association. Comparability are
based on the EuroSCORE II risk-factors and tumor type
(histology/location) and size. |